Peptide Comparison
AdipotidevsRetatrutide
A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials.
At a Glance
Quick
comparison
Dose Range
Adipotide
0.1–0.43 mg/kg
Retatrutide
1–12 mg
Frequency
Adipotide
Once daily
Retatrutide
Once weekly
Administration
Adipotide
Subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle Length
Adipotide
4-6 weeks
Retatrutide
12+ weeks
Onset Speed
Adipotide
Moderate (1-2 weeks)
Retatrutide
Moderate (1-2 weeks)
Evidence Level
Adipotide
Strong preclinical (extensive animal studies)
Retatrutide
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Fat Elimination
Metabolic Improvement
Speed of Results
Weight Loss Power
Metabolic Health
Appetite Control
Technical Data
Compound
specifications
Adipotide
Molecular Formula
C111H206N36O28S2
Molecular Weight
2611.41 g/mol
Half-Life
~24 hours
Bioavailability
High (subcutaneous injection)
CAS Number
859216-15-2
Retatrutide
Molecular Formula
C221H342N46O68
Molecular Weight
4731 g/mol
Half-Life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS Number
2381089-83-2
Protocols
Dosing
tiers
Adipotide
Retatrutide
Applications
Best
suited for
Adipotide
Targeted White Fat Reduction
Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.
Stubborn Fat Deposits
Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.
Improving Insulin Resistance
Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.
Research Applications
As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs. No other medication has matched this.
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously.
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety Profile
Side
effects
Adipotide
Common
- Elevated Serum Creatinine
- Proteinuria
- Glucosuria
- Reduced Appetite
Uncommon
- Mild Dehydration
- Injection Site Reactions
Serious
- Renal Tubular Dysfunction
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research Status
Safety
& evidence
Adipotide
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
Adipotide has been extensively studied in mice, rats, and three species of primates with consistent results. The primary safety concern is dose-dependent kidney effects, which were reversible upon stopping treatment in all studies. No cardiovascular, neurological, or hepatic adverse events were observed. The compound shows remarkable selectivity - lean animals given the same doses experienced no weight loss, suggesting it specifically targets excess fat tissue.
Contraindications
- xKidney disease or impaired renal function
- xPregnancy or breastfeeding
- xActive infections or compromised immune system
- xHistory of severe allergic reactions to peptides
- xDehydration or conditions affecting fluid balance
Retatrutide
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants. Most side effects are gastrointestinal and tend to improve over time. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xPregnancy or planning to become pregnant
- xHistory of severe pancreatitis
- xKnown allergy to GLP-1 receptor agonists
Decision Guide
Which is
right for you?
Choose Adipotide if...
- Targeted fat reduction
- Improving insulin resistance
- Reducing stubborn white adipose tissue
- Research into vascular-targeted therapies
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization